Insight Molecular Diagnostics (IMDX) Accumulated Expenses (2015 - 2026)

Insight Molecular Diagnostics has disclosed Accumulated Expenses across 12 years of filings, most recently posting $3.3 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $3.3 million, up 198.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 198.66% YoY), and the FY2025 annual result was $1.1 million, down 42.44% from the prior year.
• Accumulated Expenses came in at $3.3 million for Q1 2026 at Insight Molecular Diagnostics, up from $1.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $4.1 million in Q3 2022 to a low of $1.1 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $1.7 million (2023), against an average of $2.0 million.
• Across the five-year window, Accumulated Expenses plunged 57.66% in 2023 and surged 198.66% in 2026, its largest moves.
• Insight Molecular Diagnostics' Accumulated Expenses stood at $2.0 million in 2022, then dropped by 18.45% to $1.6 million in 2023, then gained by 17.59% to $1.9 million in 2024, then tumbled by 42.44% to $1.1 million in 2025, then soared by 198.66% to $3.3 million in 2026.
• The last three Accumulated Expenses figures came in at $3.3 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.